title: Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer.
abstract: OBJECTIVE
  A recent report demonstrated that the deletion of chromosome 8p22 could predict disease progression in stage III (capsular penetrating) prostate cancer. We studied if the status of chromosomal deletions of 8p22 could reflect pathological stage as well as patient prognosis, thereby serving as a diagnostic tool to optimize the treatment strategy in prostate cancer.
  
  
  METHODS
  A total of 97 patients (41 Japanese and 56 Swedish) were studied by the fluorescence in situ hybridization technique. Seventy-seven patients (23 pT2, 18 pT3, and 36 pN+ tumors) underwent surgery (radical prostatectomy or lymph node dissection). The specimens were prepared by touch biopsy. From another 20 cases, fine-needle aspiration biopsies were obtained.
  
  
  RESULTS
  8p22 deletions were detected in 47 (61%) and 11 (55%) specimens of 77 touch biopsies and 20 fine-needle aspiration biopsies, respectively. No significant difference was found in the frequency of 8p22 deletion between different preparations of specimens, as well as between different races (Japanese versus Swedish). The frequency of 8p22 deletion was statistically higher in patients with pT3 or more than in those with pT2 (P < 0.01). Disease progression was evaluated in 57 patients. The Cox proportional hazards model revealed 8p22 deletion to be the strongest parameter to predict disease progression (hazards ratio = 5.75; P = 0.0001).
  
  
  CONCLUSIONS
  Studies on chromosomal deletions of 8p22 by fluorescence in situ hybridization technique may serve as a genetic marker to optimize the treatment strategy in patients with prostate cancer to the optimal treatment.
authors.affiliation: Department of Urology, Yamaguchi University School of Medicine, 1-1-1 Minami-koguchi, Ube, Yamaguchi 755-8505, Japan. hidde@ymg.urban.ne.jp
authors.forename: H
authors.initials: H
authors.lastname: Matsuyama
authors.forename: Y
authors.initials: Y
authors.lastname: Pan
authors.forename: K
authors.initials: K
authors.lastname: Oba
authors.forename: S
authors.initials: S
authors.lastname: Yoshihiro
authors.forename: K
authors.initials: K
authors.lastname: Matsuda
authors.forename: L
authors.initials: L
authors.lastname: Hägarth
authors.forename: D
authors.initials: D
authors.lastname: Kudren
authors.forename: K
authors.initials: K
authors.lastname: Naito
authors.forename: U S
authors.initials: US
authors.lastname: Bergerheim
authors.forename: P
authors.initials: P
authors.lastname: Ekman
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002872:Chromosome Deletion; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D018450:Disease Progression; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007564:Japan; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology*; D016019:Survival Analysis; D013548:Sweden
chemical_list: D017430:Prostate-Specific Antigen